keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatology;biologics

keyword
https://www.readbyqxmd.com/read/28812149/-uveitis-in-spondyloarthritis
#1
REVIEW
M Rudwaleit, K Walscheid, A Heiligenhaus
Acute anterior uveitis (AAU) is the most frequent uveitis subtype. It is often associated with HLA-B27 and with inflammatory rheumatic diseases, in particular with spondyloarthritis (SpA), which itself is strongly associated with HLA-B27. About 40-60% of patients with AAU have an associated spondyloarthritis, and 20-40% of patients with spondyloarthritis also have uveitis. The incidence of AAU in patients with SpA clearly correlates with disease duration. The AAU has an acute onset, usually affects only one eye at a time, and shows a tendency for recurrence...
August 15, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28811201/the-unmet-need-in-rheumatology-reports-from-the-targeted-therapies-meeting-2017
#2
Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, Philip Mease, Mary Crow, Michael Weinblatt, Joan Bathon, Gerd R Burmester, Maxime Dougados, Johnathan Kay, Xavier Mariette, Ronald Van Vollenhoven, Joachim Sieper, Fritz Melchers, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, Daniel E Furst
The 19th annual international Targeted Therapies meeting brought together over 100 leading basic scientists and clinical researchers from around the world in the field of immunology, molecular biology and rheumatology and other specialties. During the meeting, breakout sessions were held consisting of 5 disease-specific groups with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematous, connective tissue diseases (e...
August 12, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28807652/severity-indices-in-rheumatoid-arthritis-a-systematic-review
#3
Esther Toledano, M Jesús García de Yébenes, Isidoro González-Álvaro, Loreto Carmona
OBJECTIVE: To identify tools designed to evaluate the severity of patients with rheumatoid arthritis (RA) in order to use them in the investigation of prognostic markers in early arthritis. METHODS: We conducted a systematic review of studies that developed/validated an index for RA disease severity. They were analyzed using the COSMIN checklist to assess their methodological quality. In addition, all the variables included were evaluated for their clarity of definition, feasibility and probability of being present in each outcome during the first 2 years of the disease course...
August 11, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28807650/current-state-of-biosimilars-in-mexico-the-position-of-the-mexican-college-of-rheumatology-2016
#4
Daniel Xibille, Sandra Carrillo, Gabriela Huerta-Sil, Ramiro Hernández, Leonardo Limón, Guadalupe Olvera-Soto, Luis Javier Jara-Quezada, Abdieel Esquivel, Marcela Pérez-Rodríguez
The present document is a position statement of the Mexican College of Rheumatology on the use of biosimilars in rheumatic diseases. This position considers that biosimilars should be considered as interchangeable, that automatic substitution without previous notice in stable patients during follow-up is not ethical, that the approval of a biosimilar should only be given after exhaustive review of preclinical and clinical data marked by Mexican regulations, that it should be clearly stated in the nomenclature of biologic drugs which is the innovator and which is the biosimilar, that it is not correct to choose a biosimilar as treatment based only on economic reasons or extrapolate indications based only on the approval of the innovator and in the absence of safety and efficacy data for the biosimilar...
August 11, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/28804488/anti-adhesion-therapies-in-inflammatory-bowel-disease-molecular-and-clinical-aspects
#5
REVIEW
Sebastian Zundler, Emily Becker, Carl Weidinger, Britta Siegmund
The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD was ground breaking for the concept of anti-adhesion blockade. Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28792612/problems-and-solutions-for-patients-with-fibromyalgia-building-new-helping-relationships
#6
Pilar Montesó-Curto, Montserrat García-Martinez, Sara Romaguera, María Luisa Mateu, María Teresa Cubí-Guillén, Lidia Sarrió-Colas, Anna Núria Llàdser, Stephen Bradley, María Luisa Panisello-Chavarria
AIM: To identify the main biological, psychological and sociological problems and potential solutions for patients diagnosed with fibromyalgia by use of Group Problem-Solving Therapy. BACKGROUND: Group Problem-Solving Therapy is a technique for identifying and solving problems, increasing assertiveness, self-esteem and eliminating negative thoughts. DESIGN: Qualitative phenomenological interpretive design: Group Problem-Solving Therapy sessions conducted with patients suffering fibromyalgia were studied; participants recruited via the Rheumatology Department at a general hospital and associations in Catalonia, Spain with sessions conducted in nearby university setting...
August 9, 2017: Journal of Advanced Nursing
https://www.readbyqxmd.com/read/28771892/therapeutic-depletion-of-myeloid-lineage-leukocytes-by-adsorptive-apheresis-for-psoriatic-arthritis-efficacy-of-a-non-drug-intervention-for-patients-refractory-to-pharmacologics
#7
Takuro Kanekura, Mariko Seishima, Masaru Honma, Takafumi Etou, Hikaru Eto, Keiko Okuma, Yukari Okubo, Yukie Yamaguchi, Takeshi Kambara, Tomotaka Mabuchi, Yasushi Suga, Akimichi Morita, Kiyofumi Yamanishi, Daisuke Tsuruta, Kei Itoh, Ken Yamaji, Shigaku Ikeda
Psoriatic arthritis (PsA), a chronic inflammatory arthropathy associated with psoriasis, is an intractable immune disorder and refractory to pharmacological intervention. We assessed efficacy of selective depletion of myeloid lineage leukocytes in patients with PsA in a multicenter setting. A total of 20 patients with moderate to severe PsA refractory to conventional and biological disease-modifying antirheumatic drugs were included. Eligible patients had 3 points or more in the classification criteria for PsA...
August 3, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28765712/mean-cost-per-number-needed-to-treat-with-tocilizumab-plus-methotrexate-versus-abatacept-plus-methotrexate-in-the-treatment-of-rheumatoid-arthritis-in-patients-previously-treated-with-methotrexate
#8
Maurizio Benucci, Roberto Ravasio, Arianna Damiani
INTRODUCTION: Biological disease-modifying antirheumatic drugs are particularly recommended for use in patients who are poor responders, are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs), or in whom continued treatment with cDMARDs is deemed inappropriate. We estimated the efficacy and treatment costs associated with the use of tocilizumab (TCZ) plus methotrexate (Mtx) versus abatacept (ABT) plus Mtx in the treatment of rheumatoid arthritis (RA) in patients previously treated with Mtx...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28737994/impact-of-a-patient-support-program-on-patient-adherence-to-adalimumab-and-direct-medical-costs-in-crohn-s-disease-ulcerative-colitis-rheumatoid-arthritis-psoriasis-psoriatic-arthritis-and-ankylosing-spondylitis
#9
David T Rubin, Manish Mittal, Matthew Davis, Scott Johnson, Jingdong Chao, Martha Skup
BACKGROUND: AbbVie provides a free-to-patient patient support program (PSP) to assist adalimumab-treated patients with medication costs, nurse support, injection training, pen disposal, and medication reminders. The impact of these services on patient adherence to adalimumab and direct medical costs associated with autoimmune disease has not been assessed. OBJECTIVE: To quantify the relationship between participation in a PSP and outcomes (adalimumab adherence, persistence, and direct medical costs) in patients initiating adalimumab treatment...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28734661/systematic-literature-review-and-meta-analysis-of-tumor-necrosis-factor-alpha-experienced-rheumatoid-arthritis
#10
Alvin F Wells, Jeffrey R Curtis, Keith A Betts, Kevin Douglas, Ella Xiaoyan Du, Arijit Ganguli
PURPOSE: The goal of this study was to compile all available evidence regarding the efficacy of tumor necrosis factor-α (TNF) inhibitors, non-TNF biologics, and tofacitinib for TNF-experienced patients who have rheumatoid arthritis (RA). METHODS: A systematic literature review of MEDLINE, EMBASE, and rheumatology conference abstracts was performed to identify observational studies and randomized controlled trials (RCTs) reporting American College of Rheumatology response rates (ACR 20/50/70) for adult patients with RA who switched from at least 1 TNF to another TNF or a non-TNF therapy...
July 19, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28730757/psoriatic-arthritis-treatment-regimens-therapy-duration-and-reasons-for-cessation-in-the-biologics-era-a-multi-centre-australian-study
#11
Kathleen Tymms, Ayano Kelly, Paul Bird, Hedley Griffiths, Julien de Jager, Geoff Littlejohn, Sandra Louw, Lynden Roberts, Peter Youssef, Jane Zochling, Dave Nichols
AIM: To describe the treatment regimens, duration of therapy and reasons for disease-modifying antirheumatic drug (DMARD) cessation in a large psoriatic arthritis (PsA) cohort. METHODS: A retrospective non-interventional multi-centre study using Audit4 electronic medical records, with de-identified, routinely collected clinical data from rheumatology practices in the OPAL consortium (Optimising Patient outcomes in Australian rheumatoLogy) during November 2015. Baseline characteristics, type and duration of conventional and biologic DMARDs (cDMARD and bDMARD, respectively), disease activity (Disease Activity Score of 28 joints C-reactive protein [DAS28-CRP]), and reasons for treatment cessation were recorded...
July 21, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28730751/tuberculosis-and-biologics-in-rheumatology-india-a-special-situation
#12
REVIEW
Rohini Handa, Sundeep Upadhyaya, Sanjiv Kapoor, Ramesh Jois, Bimlesh D Pandey, Anuj K Bhatnagar, Ashwani Khanna, Vishal Goyal, Kamal Kumar
India has a huge patient burden of rheumatic diseases (RDs) including rheumatoid arthritis. The use of biologics has transformed the treatment paradigm for RD; however, biologic treatment-related infections (especially tuberculosis [TB]) are an area of potential concern for TB-endemic nations like India. Anti-tumor necrosis factor (TNF) therapy impairs the physiological TNF-mediated signaling and may cause reactivation and dissemination of latent TB infection (LTBI). Careful screening is, thus, crucial in RD patients who are about to commence anti-TNF treatment...
July 21, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28725955/biologics-in-juvenile-idiopathic-arthritis-a-narrative-review
#13
REVIEW
Federica Vanoni, Francesca Minoia, Clara Malattia
In the past years, pediatric rheumatology has seen a revolution in the treatments for rheumatic diseases, particularly juvenile idiopathic arthritis. Even if nonsteroidal anti-inflammatory drugs (NSAID), intra-articular corticosteroids (IAC) injections, and methotrexate remain the mainstay of the treatment for JIA patients, in aggressive disease, these treatments may be not sufficient to reach disease remission and to prevent long-term disability. Comprehension of immunological mechanisms involved in the pathogenesis of the diseases allowed to conceive new drugs targeting specific steps of the immune response...
July 20, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28721016/a-review-of-the-literature-analyzing-benefits-and-concerns-of-infliximab-biosimilar-ct-p13-for-the-treatment-of-rheumatologic-diseases-focus-on-interchangeability
#14
REVIEW
Andrea Becciolini, Maria Gabriella Raimondo, Chiara Crotti, Elena Agape, Martina Biggioggero, Ennio Giulio Favalli
The introduction of biological agents drastically changed the treatment paradigm of inflammatory arthritides, ameliorating the natural history of the diseases but concomitantly increasing the drug costs due to the manufacturing process. On this concern, biosimilar drugs may represent a valid option for reducing this elevated cost and increasing the availability of these highly effective treatments. Recently, CT-P13, the first biosimilar of infliximab, has been approved with the same indications established for the reference product (RP), and its daily use is progressively increasing...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28712320/certolizumab-pegol-treatment-in-behcet-s-disease-with-different-organ-involvement-a-multicenter-retrospective-observational-study
#15
Giuseppe Lopalco, Giacomo Emmi, Stefano Gentileschi, Silvana Guerriero, Antonio Vitale, Elena Silvestri, Matteo Becatti, Iacopo Cavallo, Claudia Fabiani, Bruno Frediani, Florenzo Iannone, Luca Cantarini
OBJECTIVES: The purpose of the present study was to describe our experience with the recombinant Fab' antibody fragment against TNF-α Certolizumab Pegol (CZP) in patients with Behçet's disease (BD) refractory to standardized therapies and previous biologic agents. METHODS: Retrieved data including demographic characteristics, clinical manifestations, and previous treatments were collected in three different specialized Rheumatologic Units in Italy. In order to evaluate disease activity, the BD current activity form (BDCAF) has been used before starting CZP therapy and at each visit during treatment...
February 21, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28690730/septic-arthritis-of-the-pubis-symphysis-clinical-and-therapeutic-features
#16
Zeineb Alaya, Houneida Zaghouani, Walid Osman, Lassad Hassini, Nader Naouar, Mohamed Laziz Ben Ayèche, Elyès Bouajina
Septic arthritis of the pubis symphysis is rare and difficult to diagnose. The objective of our study was to describe the biological, clinical, radiological and therapeutic aspects of this disease. This is a retrospective study of 4 cases of septic arthritis of the pubic symphysis collected in the Department of Rheumatology and Orthopaedics in Sousse in Tunisia over a period of 16 years (2000-2016). Our population consists of 3 women and one men. The mean age was 47 years (18-83). Clinical signs of appeal were inflammatory groin pain, pubic pain and fever...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28687159/15-years-of-the-histopathological-synovitis-score-further-development-and-review-a-diagnostic-score-for-rheumatology-and-orthopaedics
#17
REVIEW
V Krenn, G Perino, W Rüther, V T Krenn, M Huber, T Hügle, A Najm, S Müller, F Boettner, F Pessler, W Waldstein, J Kriegsmann, R Casadonte, T Häupl, S Wienert, M G Krukemeyer, S Sesselmann, S Sunitsch, R Tikhilov, L Morawietz
The histopathological synovitis score evaluates the immunological and inflammatory changes of synovitis in a graduated manner generally customary for diagnostic histopathological scores. The score results from semiquantitative evaluation of the width of the synovial surface cell layer, the cell density of the stroma and the density of the inflammatory infiltration into 4 semiquantitative levels (normal 0, mild 1, moderate 2, severe 3). The addition of these values results in a final score of 0-9 out of 9. On the basis of this summation the condition is divided into low-grade synovitis and high-grade synovitis: A synovitis score of 1 to≤4 is called low-grade synovitis (arthrosis-associated/OA synovitis, posttraumatic synovitis, meniscopathy-associated synovitis and synovitis with haemochromatosis)...
August 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28677075/urticarial-reaction-to-ustekinumab-during-the-treatment-of-plaque-psoriasis-in-a-hepatitis-c-positive-patient
#18
Christopher H Chu, Charles Davis
A 62-year-old white woman with a history of hepatitis C and type 2 diabetes mellitus developed urticaria during treatment with ustekinumab for plaque psoriasis. The patient received two 45-mg ustekinumab injections in her first 2 months and then one 45-mg injection every 3 months for her psoriasis. After 10 months, she developed a round red rash on her skin diffusely on her body. She also complained of joint pain in her hands. Rheumatology became involved, and investigations revealed that her antinuclear antibody titer was negative, but her rheumatoid factor, erythrocyte sedimentation rate, and liver function enzymes were elevated...
December 2017: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/28662006/-turmeric-not-only-spice
#19
EDITORIAL
Zygmunt Zdrojewicz, Marta Szyca, Ewa Popowicz, Tomasz Michalik, Bartłomiej Śmieszniak
The purpose of this article is to introduce the role of turmeric in medicine and summarize the current state of research on its applications. Turmeric (Curcuma longa) has had a wide range of uses in middle eastern and orietnal traditional medicine. Currently, however, its use has been truncated to a common cooking spice, despite numerous studies pointing to its healing properties and possible use in the treatment of many diseases. The main focus is on curcumin, a polyphenol which serves as the biologically active component of turmeric...
June 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/28658988/updates-on-the-treatment-of-gout-including-a-review-of-updated-treatment-guidelines-and-use-of-small-molecule-therapies-for-difficult-to-treat-gout-and-gout-flares
#20
Rose Soskind, Daniel T Abazia, Mary Barna Bridgeman
Gout is a rheumatologic condition associated with elevated serum uric acid levels and deposition of monosodium urate crystals in joints and soft tissues. Areas covered: In this article, we describe the role of currently available drug therapies for managing acute gout flares and used in reducing serum urate levels. Further, we explore the role of novel small molecular therapies and biologic agents in the treatment of refractory or severe gout symptoms. A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations Databases (1996-June 2017) was conducted utilizing the key words 'gout', 'interleukin-1 inhibitors', 'acute gout', 'gout treatment', 'urate lowering therapies', 'hyperuricemia', 'colchicine', 'pegloticase', 'lesinurad', 'xanthine oxidase', 'xanthine oxidase inhibitors', 'allopurinol', 'febuxostat', 'uricosurics', 'probenecid', and 'benzbromarone'...
August 2017: Expert Opinion on Pharmacotherapy
keyword
keyword
47772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"